Press Releases
Latest ¦ 2012 ¦ 2011 ¦ Archive
May 6, 2013
Concert Pharmaceuticals Announces Strategic Collaboration with Celgene Corporation to Develop Deuterium-Modified Compounds
April 23, 2013
Concert Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
February 27, 2013
Concert Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 5, 2013
February 26, 2013
Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate
February 19, 2013
Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease
February 7, 2013
Concert Pharmaceuticals Announces Milestone Achievement in Avanir Pharmaceuticals Collaboration
[ back to top ]
_____________________________________________________________________________________
December 10, 2012
Concert Pharmaceuticals Presents Findings Demonstrating Enhanced
Potency of CTP-221, a Deuterated S-Enantiomer of Lenalidomide
November 27, 2012
Concert Pharmaceuticals’ Partner Avanir Pharmaceuticals Provides Clinical Study Update on
CTP-786/AVP-786
November 27, 2012
Concert Pharmaceuticals’ CTP-499 for Diabetic Kidney Disease Selected as a Top 10 Project to Watch by Windhover
November 5, 2012
Concert Pharmaceuticals Announces Poster Presentation at the 2012 American Society of Hematology Annual Meeting
November 1, 2012
Concert Pharmaceuticals Presents Preclinical Results Demonstrating CTP-499, a Novel Treatment for Diabetic Kidney Disease, Ameliorated Renal Fibrosis and Inflammation In Vivo; Data Presented at Kidney Week 2012
October 22, 2012
Concert Pharmaceuticals Announces Issuance of U.S. Patent for its Lead Drug Candidate CTP-499
October 11, 2012
Concert Pharmaceuticals Announces Preclinical Poster Presentation at the American Society of Nephrology Kidney Week 2012
August 8, 2012
Concert Pharmaceuticals to Present at the 2012 Wedbush PacGrow Life Sciences Conference on August 15, 2012
May 11, 2012
Concert Pharmaceuticals Presents Clinical Results Demonstrating CTP-499 is Well-Tolerated in Patients with Stage 3 Chronic Kidney Disease; Results Presented at National Kidney Foundation 2012 Spring Clinical Meetings
March 29, 2012
Concert Pharmaceuticals to Present at the Needham 2012 Healthcare
Conference on April 3, 2012
March 5, 2012
Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating
CTP-499 for the Treatment of Diabetic Nephropathy
March 5, 2012
Concert Pharmaceuticals and Fast Forward Announce Collaboration to
Advance Novel Treatment for Spasticity and Pain in Multiple Sclerosis
February 29, 2012
Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-Modified Dextromethorphan for Disorders of the Nervous System
February 28, 2012
Concert Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference on March 6, 2012
January 30, 2012
Concert Pharmaceuticals to Present at Epilepsy Pipeline Update Conference
January 18, 2012
New Patents Expand Concert Pharmaceuticals’ Patent Estate of Deuterium-Based Therapeutics; 25 Patents Issued Worldwide
January 3, 2012
Concert Pharmaceuticals to Present at the J.P. Morgan Healthcare
Conference on January 10, 2012
[ back to top ]
November 21, 2011
Concert Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference on November 30, 2011
November 15, 2011
Concert Pharmaceuticals Announces NIH Research Collaboration for Rare and Neglected Diseases
November 14, 2011
Concert Pharmaceuticals Presents Preclinical Data for Novel GABA(A) Subtype-Selective Modulator at Neuroscience 2011; Potential Treatment for Multiple GABA-Based Disorders Including Spasticity and Pain
November 14, 2011
Concert Presents Phase 1 Data for CTP-499 at ASN Kidney Week Meeting; Supports Advancement into Phase 2 in Diabetic Nephropathy Patients
October 19, 2011
Concert Pharmaceuticals Announces CTP-499 Data Presentations at the American Society of Nephrology (ASN) Kidney Week Meeting
October 19, 2011
Concert Pharmaceuticals Announces Data Presentations at Neuroscience
2011; Demonstrates Potential of Deuterium-Containing GABAA Modulators
September 29, 2011
Concert Pharmaceuticals Announces Issuance of 15th US Patent Supporting DCE Platform™ Approach; Receives New Patent for Use of C-21191 in Spasticity
August 9, 2011
Concert Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
July 20, 2011
Concert Pharmaceuticals’ Deuterium-Modified Boceprevir Demonstrates Enhanced Metabolic Stabilization and Improved Drug Properties; Findings Published in Journal of Labelled Compounds and Radiopharmaceuticals
June 20, 2011
Concert Pharmaceuticals Announces Milestone Achievement in GlaxoSmithKline Collaboration
June 20, 2011
Concert Pharmaceuticals Announces Advancement of Novel Drug
Candidates in Kidney Disease and Spasticity
May 2, 2011
Concert Pharmaceuticals Presents Preclinical Data on Novel Deuterium-Containing Drug Compound at Antiepileptic Drug Trials XI Conference; Sigma-1 Agonist, C-10068, Shown to Have Anti-Convulsant and Neuroprotective Effects
April 12, 2011
Concert Pharmaceuticals Expands Regulatory and Clinical Leadership with New Appointments
Mark Roessel Named Vice President of Regulatory Affairs and Quality Assurance; LuAnn Sabounjian Named Vice President, Clinical Operations
March 29, 2011
Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study; First-in-Class Drug Candidate from Deuterium Platform Has Anti-Inflammatory, Anti-Fibrotic, and Anti-Oxidant Properties
March 29, 2011
Concert Pharmaceuticals to Present at the Needham Healthcare Conference on April 5, 2011
March 1, 2011
Concert Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference on March 8
February 2, 2011
Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound; Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases and Injuries
January 19, 2011
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals; Additional Management Team Announcement with Promotion of Robert Silverman
January 13, 2011
New Patents Continue to Issue for Concert Pharmaceuticals Deuterium Chemistry Intellectual Property Estate
[ back to top ]
|
